BioSpace

Summit snags $2B investment from AstraZeneca, clearing financial overhang

The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.

作者 BioSpace

1 分钟阅读
Summit snags $2B investment from AstraZeneca, clearing financial overhang
Summit snags $2B investment from AstraZeneca, clearing financial overhang

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察